A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Completed · Phase 2 · Has a placebo group
Conditions studied: Norovirus Infections
In brief
This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS co-administered (bivalent delivery) against a matching placebo arm. Bivalent GI.1 and GII.4 vaccines are being investigated for the prevention of noroviral gastroenteritis caused by norovirus GI.1 and GII.4.
Key facts
- Study ID
- NCT05626803
- Run by
- Vaxart
- People needed
- 135
- Starts
- 2023-01-26
- Expected to finish
- 2023-10-16
- Last updated by the study team
- 2025-04-15
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Ark Clinical Research — Long Beach, California, United States
- Johnson County Clin-Trials — Lenexa, Kansas, United States
- Nucleus Network Pty Ltd — Saint Paul, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.